Induction of Type I Diabetes Mellitus in Beagle Dogs Using Alloxan and Streptozotocin. Issue 11 (3rd November 2022)

• Record Type: Journal Article
• Authors: Araujo, Joseph; Paradis, Andrea; Mendes, Jessica; Petrik, Shawn; de Rivera, Christina
• Is Part Of: Current protocols. Volume 2:Issue 11(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-11-03
• Subjects: alloxan -- canine diabetes model -- hyperglycemia -- streptozotocin -- type I diabetes mellitus; Life sciences -- Laboratory manuals -- Periodicals; Biology -- Laboratory manuals -- Periodicals; Life sciences -- Technique -- Periodicals; Biology -- Technique -- Periodicals; 570.028
• DOI: 10.1002/cpz1.580
• Languages: English
• ISSNs: 2691-1299

Abstract

Abstract: This article describes a protocol for chemically inducing type I diabetes mellitus in beagle dogs using a mixture of alloxan (ALX) and streptozotocin (STZ). ALX and STZ are both cytotoxic, diabetogenic agents that cause necrosis of pancreatic β‐cells and therefore halt the production of insulin. Although both compounds are widely used in experimental animal models of diabetes, standard protocols employing a single high dose of either agent are also implicated in adjacent organ damage. In contrast, combined administration of ALX and STZ allows for the use of lower doses, a method that effectively destroys β‐cells and circumvents unwanted adverse effects. The procedures described in this protocol produce persistent, insulin‐dependent hyperglycemia in beagle dogs using combined doses of ALX and STZ lower than those previously described for a single intravenous administration. This model can be used to test experimental compounds indicated for the treatment of diabetes. © 2022 Wiley Periodicals LLC. Basic Protocol : Induction of type I diabetes mellitus in beagle dogs using alloxan and streptozotocin